Biogen strikes $600m deal with Pfizer for promising schizophrenia drug
Biogen, a leading US biotechnology firm, has reached a significant agreement to acquire Pfizer's neurology drug candidate, PF-04958242, which is being developed to address cognitive ... Read More
Merck to acquire Australian biotech firm Viralytics for $394m to bolster oncolytic immunotherapy treatments
Significant Acquisition in Pharma Industry: US pharmaceutical giant Merck has announced a definitive agreement to acquire Viralytics, an Australian biotech company, for AUD 502 million ... Read More
Roche set to fully acquire Flatiron Health in $1.9bn deal to accelerate cancer drug development
Roche, the Swiss pharmaceutical giant, has announced its plans to fully acquire Flatiron Health, a leading oncology software company, for $1.9 billion. This strategic move ... Read More
Seattle Genetics to acquire Cascadian Therapeutics for $614m to bolster oncology portfolio
Seattle Genetics, a leader in oncology biotechnology, has announced the acquisition of Cascadian Therapeutics for approximately $614 million, a strategic move to enhance its portfolio ... Read More
Sanofi to acquire Belgian biotech firm Ablynx for €3.9bn in all-cash deal
French pharmaceutical giant Sanofi has successfully finalized an agreement to acquire Ablynx, a Belgian biotechnology firm, for approximately €3.9 billion. This strategic acquisition surpasses a ... Read More
Sanofi to acquire Bioverativ for $11.6bn to expand into rare blood disorders
Sanofi has announced a definitive agreement to acquire Bioverativ, a US biotechnology company specializing in the treatment of hemophilia and other rare blood disorders, for ... Read More
Takeda Pharmaceutical set to acquire TiGenix for €520m, enhancing gastroenterology and specialty care offerings
Japanese pharmaceutical giant Takeda Pharmaceutical has announced a proposal to acquire TiGenix, a Belgium-based cell therapy company, for €520 million. This acquisition is aimed at ... Read More
Mallinckrodt to acquire Sucampo Pharmaceuticals in $1.2bn deal
In a strategic move to broaden its pharmaceutical offerings, UK-based Mallinckrodt has announced the acquisition of Sucampo Pharmaceuticals, including its commercial and developmental assets, for ... Read More
Roche to acquire Ignyta for $1.7bn to enhance oncology portfolio
Roche Pharmaceuticals, a prominent Swiss pharmaceutical company, has entered into a definitive merger agreement to acquire Ignyta, a U.S. cancer drug maker, for $1.7 billion ... Read More
Teva Pharmaceutical announces major global restructuring with 14,000 job cuts
Teva Pharmaceutical Industries, the Israel-based generic drug manufacturer, has unveiled a drastic two-year restructuring plan aimed at rejuvenating its business and enhancing financial performance. The ... Read More